As Amarin Corp. PLC heads into a US Food and Drug Administration Advisory Committee meeting for Vascepa, the CEO has an optimistic outlook for being able to pursue a large commercial launch. Speaking to Scrip, CEO John Thero said that anything less than success would be a huge blow for them as they are a single-product company with a “blockbuster-sized” commercial opportunity on their hands. Scrip looks at the effects of labeling expansion delays on the company, the lack of a backup plan, but the wind at the company’s back as they head into their meeting.